Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-3-12
pubmed:abstractText
Concomitant resistance, the phenomenon whereby a primary malignancy inhibits the growth of metastatic lesions, is likely caused by the production of endogenous anti-angiogenic factors. The purpose of this study was to evaluate the influence of the angiogenesis inhibitor, endostatin, expressed by primary sites of neuroblastoma, on synchronous disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1531-5037
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
405-11; discussion 405-11
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15017561-Analysis of Variance, pubmed-meshheading:15017561-Angiogenesis Inhibitors, pubmed-meshheading:15017561-Angiography, pubmed-meshheading:15017561-Animals, pubmed-meshheading:15017561-Apoptosis, pubmed-meshheading:15017561-Cell Line, Tumor, pubmed-meshheading:15017561-Disease Models, Animal, pubmed-meshheading:15017561-Endostatins, pubmed-meshheading:15017561-Immunohistochemistry, pubmed-meshheading:15017561-In Situ Nick-End Labeling, pubmed-meshheading:15017561-Liver Neoplasms, pubmed-meshheading:15017561-Mice, pubmed-meshheading:15017561-Mice, SCID, pubmed-meshheading:15017561-Neoplasm Transplantation, pubmed-meshheading:15017561-Neoplasms, Second Primary, pubmed-meshheading:15017561-Neovascularization, Pathologic, pubmed-meshheading:15017561-Neuroblastoma, pubmed-meshheading:15017561-Skin Neoplasms
pubmed:year
2004
pubmed:articleTitle
Endostatin-mediated concomitant resistance in neuroblastoma.
pubmed:affiliation
Department of Surgery, St Jude Children's Research Hospital and University of Tennessee College of Medicine, Memphis, TN 38105, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't